Treatment with bendamustine plus rituximab (B-R) doubles progression free survival (PFS) compared with current standard of care CHOP-R (69.5 versus 31.2 months; p Results from the StiL NHL-1 study published in The Lancet this week show that a first-line treatment regimen of bendamustine plus...